Utility of Lung Clearance Index Score as a Noninvasive Marker of Deployment Lung Disease

NCT03012958 | Completed DMC

• 1 other identifier: HS-2851
• Study Type: observational
• Target: 73
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to learn more about new noninvasive ways of detecting lung disease in US Military personnel and people who worked as contractors during military operations in Iraq and Afghanistan. This study is looking at conducting a type of breathing test called the lung clearance index (LCI) test which is being investigated as a potential noninvasive way to detect the type of lung disease that may be seen in symptomatic deployers retuning from Iraq and Afghanistan.

Conditions

Bronchiolitis; Pneumonitis; Dyspnea

Outcome Measures

Primary Outcomes (1)

• LCI parameters in symptomatic deployers compared to normal adults to determine whether LCI is an early marker of lung injury.

  Average of three acceptable trials

  Up to 24 months

Secondary Outcomes (1)

• Correlation between LCI score and the clinical characteristics of the population of deployers.

  Up to 24 months

Study Arms (2)

Health control group

Who are 18 years or older, have no history of pre-existing lung disease, and report no respiratory illness in the four weeks preceding enrollment. This study consist of one visit: If the potential subject meets the Inclusion and exclusion then they will have the LCI testing.

Other: Lung clearance index (LCI)

Deployment-related lung disease

Defined as the presence of unexplained chest symptoms in a deployer who, on surgical lung biopsy is found to have bronchiolitis or granulomatous pneumonitis without other known causes. This study consist of one visit: If the potential subject meets the Inclusion and exclusion then they will have the LCI testing.

Other: Lung clearance index (LCI)

Interventions

Lung clearance index (LCI) OTHER

LCI is determined by the number of lung volume turnovers necessary to clear the lungs of an inert tracer gas such as nitrogen that is inhaled at the beginning of the test. The LCI is calculated by determining the cumulative expired volume (CEV) and then dividing the CEV by the functional residual capacity. Values of less than7.0 indicate normal values while an LCI greater than 7.0 is associated with heterogeneity in ventilation and distal airway abnormalities. The ability to detect peripheral airway disease may make LCI a better modality for detecting distal airways abnormalities seen on lung histopathology but often missed on traditional pulmonary function testing.

Deployment-related lung disease; Health control group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Symptomatic military deployers with deployment-related lung disease seen at National Jewish Health and healthy controls subjects.

You may qualify if:

• For the deployer group:
• presence of respiratory symptoms (cough, chest tightness, wheezing, shortness of breath or decreased exercise tolerance) following deployment
• history of deployment for Operation Iraqi Freedom, Operation Enduring Freedom or Operation New Dawn for greater than or equal to 6 weeks as either military personnel or a civilian contractor
• prior VATS biopsy-proven histologic abnormalities of small airways disease.
• For the control group:
• no history of pre-existing lung disease
• no respiratory illness in the four weeks preceding enrollment

You may not qualify if:

• For the deployer group:
• If on clinical evaluation they were found to have asthma, vocal cord dysfunction or other explanations for their respiratory symptoms and did not need to undergo surgical lung biopsy for diagnosis.
• unable to provide informed consent
• pregnant subjects
• For the control group:
• pre-existing lung disease
• unable to provide informed consent
• pregnant subjects

Sponsors & Collaborators

• National Jewish Health: lead

Study Sites (1)

National Jewish Health

Denver, Colorado, 80206, United States

Location

Related Publications (2)

• Krefft SD, Strand M, Smith J, Stroup C, Meehan R, Rose C. Utility of Lung Clearance Index Testing as a Noninvasive Marker of Deployment-related Lung Disease. J Occup Environ Med. 2017 Aug;59(8):707-711. doi: 10.1097/JOM.0000000000001058.

  PMID: 28665837 BACKGROUND

• Zell-Baran LM, Krefft SD, Moore CM, Wolff J, Meehan R, Rose CS. Multiple breath washout test data for healthy controls. Data Brief. 2020 Dec 10;34:106641. doi: 10.1016/j.dib.2020.106641. eCollection 2021 Feb.

  PMID: 33365370 BACKGROUND

MeSH Terms

Conditions

Bronchiolitis; Pneumonia; Dyspnea

Condition Hierarchy (Ancestors)

Bronchitis; Respiratory Tract Infections; Infections; Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiration Disorders; Signs and Symptoms, Respiratory; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: January 3, 2017
• First Posted: January 6, 2017
• Study Start: July 1, 2014
• Primary Completion: May 1, 2018
• Study Completion: May 1, 2018
• Last Updated: January 8, 2021

Record last verified: 2021-01

Locations

US (1)